Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study by Ancona S, Armstrong K, Longo C, Rabone R, Merrick V, Henderson P, Gandullia P, Wilson DC, Arrigo S, Russell RK

Subjects: Get full text

Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease by Eva Vermeer, Jasmijn Z. Jagt, Eline M. Lap, Eduard A. Struys, Andries E. Budding, Nanda M. Verhoeven-Duif, Marjolein Bosma, Johan E. van Limbergen, Bart G.P. Koot, Robert de Jonge, Marc A. Benninga, Animesh Acharjee, Nanne K.H. de Boer, Tim G.J. de Meij

Subjects: “…Paediatric inflammatory bowel disease…”
Get full text

Safety and efficacy of pharmacological approaches available for multisystem inflammatory syndrome in children (MIS-C): a systematic review by Yasothaa Velusamy, Govinathan Vivekanandan, Muhammad Hibatullah Romli, Aissvarya Shankar, Thilakavathy Karuppiah, Putri Yubbu

Subjects: Get full text